Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance

Hou,Xiao-Wei; Bai,Chen-Guang; Liu,Xiao-Hong; Qiu,Cen; Huang,Ling; Xu,Jing-Jing; Ma,Da-Lie

doi:10.3892/ol.2012.1019

Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance

Authors:
- Xiao-Wei Hou
- Chen-Guang Bai
- Xiao-Hong Liu
- Cen Qiu
- Ling Huang
- Jing-Jing Xu
- Da-Lie Ma
View Affiliations

Affiliations: Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Institute of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: November 9, 2012 https://doi.org/10.3892/ol.2012.1019
Pages: 552-558

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

KIT autophosphorylation caused by mutation of KIT is considered to be a critical mechanism for the oncogenesis of gastrointestinal stromal tumors (GISTs). However, little is known regarding whether stem cell factor (SCF), the KIT ligand, is able to induce the proliferation of GIST cells by activating the wild-type KIT receptor in GISTs. Imatinib, a tyrosine kinase inhibitor, has been demonstrated to be effective as treatment for the majority of GISTs. However, primary resistance to imatinib in GISTs with wild-type KIT and acquired resistance in GISTs with mutant KIT are becoming increasingly significant problems. The aims of this study were to detect the expression and function of SCF in 68 GIST samples, and to explore the relationship between SCF activity and imatinib resistance using immunohistochemical staining and western blot analysis. Results showed abundant expression of SCF in GISTs and demonstrated that SCF is capable of enhancing GIST cell proliferation. Similar to its ineffectiveness in wild‑type GISTs, imatinib also failed to inhibit SCF‑induced KIT activation in GISTs with mutant KIT. We also found increased SCF expression in GIST cells treated with imatinib. Overall, our results indicated that SCF‑induced KIT activation is a novel essential pathway for the proliferation of GISTs. Imatinib was not able to inhibit the activity of SCF, while it promoted the expression of SCF, which may have contributed to acquired imatinib resistance.

View Figures

View References

1.	Rousset D, Agnès F, Lachaume P, André C and Galibert F: Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin like domains. J Mol Evol. 41:421–429. 1995. View Article : Google Scholar : PubMed/NCBI
2.	Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD and Cosman D: Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell. 63:235–243. 1990. View Article : Google Scholar : PubMed/NCBI
3.	Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE and Toyama K: Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood. 85:641–649. 1995.PubMed/NCBI
4.	Cohen PS, Chan JP, Lipkunskaya M, Biedler JL and Seeger RC: Expression of stem cell factor and c-kit in human neuroblastoma. The children’s cancer group. Blood. 84:3465–3472. 1994.
5.	Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A, Funasaka Y, Okada A, Maekawa T, He-Yao W and Chiba T: Expression of proto-oncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci. 43:8–14. 1998. View Article : Google Scholar : PubMed/NCBI
6.	Hines SJ, Organ C, Kornstein MJ and Krystal GW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ. 6:769–779. 1995.PubMed/NCBI
7.	Inoue M, Kyo S, Fujita M, Enomoto T and Kondoh G: Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 54:3049–3053. 1994.PubMed/NCBI
8.	Krystal GW, Hines SJ and Organ CP: Organ. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 56:370–376. 1996.PubMed/NCBI
9.	Pietsch T, Kyas U, Steffens U, Yakisan E, Hadam MR, Ludwig WD, Zsebo K and Welte K: Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors. Blood. 80:1199–206. 1992.PubMed/NCBI
10.	Toyota M, Hinoda Y, Takaoka A, Makiguchi Y, Takahashi T, Itoh F, Imai K and Yachi A: Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol. 14:295–302. 1993. View Article : Google Scholar : PubMed/NCBI
11.	Kindblom LG, Remotti HE, Aldenborg F and Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 152:1259–1269. 1998.
12.	Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
14.	Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:8118–8121. 2001.PubMed/NCBI
15.	Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R and Merkelbach-Bruse S: Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 106:887–895. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Emile JF, Théou N, Tabone S, Cortez A, Terrier P, Chaumette MT, Julié C, Bertheau P, Lavergne-Slove A, Donadieu J, Barrier A, et al: A clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol. 2:597–605. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, et al EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 42:1093–1103. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD and Joensuu H: Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with Imatinib. Blood. 103:2929–2935. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Hirano K, Shishido-Hara Y, Kitazawa A, Kojima K, Sumiishi A, Umino M, Kikuchi F, Sakamoto A, Fujioka Y and Kamma H: Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): a potential marker for tumor proliferation. Pathol Res Pract. 204:799–807. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Théou-Anton N, Tabone S, Brouty-Boyé D, Saffroy R, Ronnstrand L, Lemoine A and Emile JF: Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer. 94:1180–1185. 2006.PubMed/NCBI
23.	Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD and Fletcher JA: Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 23:3999–4006. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD and Fletcher JA: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 156:791–795. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Théou N, Tabone S, Saffroy R, Le Cesne A, Julié C, Cortez A, Lavergne-Slove A, Debuire B, Lemoine A and Emile JF: High expression of both mutant and wild-type alleles of c-KIT in gastrointestinal stromal tumors. Biochim Biophys Acta. 1688:250–256. 2004.PubMed/NCBI
26.	Pedersen M, Rönnstrand L and Sun J: The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Cell Signal. 21:413–418. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, Théou-Anton N, Lemoine A, Blay JY and Emile JF: KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res. 14:2285–2294. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E and Pilotti S: Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol. 217:103–112. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Hofmann UB, Kauczok-Vetter CS, Houben R and Becker JC: Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res. 15:324–329. 2009. View Article : Google Scholar : PubMed/NCBI